INTRODUCTION
An essential step for HIV-1 viral transcription from the long terminal repeat (LTR) is the recognition of TAR RNA by the viral protein Tat, acting in cooperation with two cellular proteins cyclin T1 and kinase CDK9 1, 2 . Since Tat-TAR interaction inhibitors block full-length transcription and thus suppress viral replication, they are potential anti-HIV drugs. Although a number of molecules have been designed to target TAR RNA and inhibit Tat-dependent trans-activation, a good clinical candidate has not been found so far 3 . Alternatively, much higher binding specificity to the TAR RNA stem-loop can be provided by use of oligonucleotide trans-activation inhibitors, either as aptamers 4 or as steric block oligonucleotides [5] [6] [7] . In previous studies 5, 7 , we have shown that 2'-O-methyl oligoribonucleotide mixmers containing locked nucleic acid (LNA) residues inhibit the HIV LTR trans-activation in a stably integrated plasmid reporter system in Hela cells when delivered by cationic lipid 8 . Despite some structural differences, most lipid-based transfection agents contain molecules with positively charged heads, which interact electrostatically with the negatively charged phosphodiester groups of oligonucleotide backbones. The resultant neutral "lipoplex" has a hydrophobic surface, formed by the hydrocarbon tails of the transfection agent, and is able to penetrate the outer membranes of different cell types 8 . However many cationic lipids are cytotoxic and unstable in vivo, making them appear less suitable for therapeutic use. One possible solution is to identify modified oligonucleotides that might themselves be better able to permeate cell membranes. Towards this end, we have begun to test oligonucleotides with altered backbone, especially some containing amino groups that may have reduced negative charge, for their ability to bind a model TAR RNA and to inhibit the HIV-1 Tat-dependent transactivation in Hela cell reporter system.
RESULTS AND DISCUSSION
Here we have compared different oligonucleotides (Fig. 1b-e) , which contain basic amino groups on the backbone, to the corresponding 2'-O-methyl oligoribonucleotide and to a 2'-O-methyl oligoribonucleotide mixmer containing LNA residues previously reported 7 .
Collection Symposium Series (Vol. The oligonucleotides were assayed for their binding strengths to the structured TAR RNA model system (Fig. 1a) by use of a gel mobility shift assay developed previously 11 ( Table I ). The highest binding affinity was observed for the NPS oligo IIb. Whereas the 2'-amino-LNA/OMe mixmer IIIb was more strongly bound to TAR in the higher salt buffer (transcription buffer), surprisingly the 2'-amino-LNA/2'-glycylamino-LNA/OMe derivative IIIc showed weaker affinity to TAR RNA than mixmer IIIa, but only marginally weaker in lower salt buffer. Although 16 TAR OMe (oligo I) has reasonable binding strength to TAR RNA, it is unable to inhibit HIV-1 Tatmediated transcription trans-activation in Hela cells when delivered by cationic lipid (Fig. 2) , as shown previously 5 . By contrast, specific knockdown of Firefly luciferase expression was observed for all the other tested steric block oligonucleotides after 3 h transfection with Lipofectamine 2000. The inhibition activity varies depending on the nature of cationic lipid used. For example NP and NPS sequences were entirely inactive when delivered by Effectine 12, Oligofectamine or cationic surfactant GS 11/ DOPE 12 . The results show that several types of steric block oligonucleotide are active when delivered by Lipofectamine 2000.
All oligonucleotides were tested also in the cell reporter assay by free uptake. None of them showed inhibition of Firefly Luciferase expression or control Renilla Luciferase up to 5 µM concentration tested after 5 h delivery. This is explained by lack of cell and nuclear uptake. Thus, fluorescein- labeled sequences IIIa and IIIb showed no uptake by confocal microscopy but weak cytoplasmic uptake was observed for oligo IIIc (data not shown).
The results suggest that introduction of basic groups may help in improving the oligonucleotide free uptake. However release from endosomes may require also introduction on the oligonucleotide backbone of hydrophobic groups capable of disrupting the endosomal membrane.
